Cabozantinib for metastatic castration-resistant prostate cancer (mCRPC) following docetaxel: Combined analysis of two phase III trials.

出版年份 2018 全文链接

标题

作者

关键词

出版物

Volume 36, Issue 6_suppl, Pages 225-225

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2018-02-27

DOI

10.1200/jco.2018.36.6_suppl.225

Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.

Create Now

Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.

Get Started